Nithya Desikan has been our Chief Commercial Officer since August 2017. She is a seasoned biotechnology executive, with over 15 years of experience commercializing new therapies in domestic and global markets. Nithya joined Rhythm from Biogen Inc., where she served most recently as Vice President and Asset Executive, TECFIDERA®, overseeing the product’s global P&L and supporting the product’s position as the #1 prescribed oral therapy in multiple sclerosis. Earlier, Nithya held roles in Biogen’s Hematology business, leading cross-functional teams to drive the growth of ALPROLIX® and ELOCTATE® and the development of multiple preclinical assets. Before that, Nithya built the strategy to support the US launch of ALPROLIX, Biogen’s first entrant into the orphan hemophilia market. Before joining Biogen Inc., Nithya spent 12 years at Johnson & Johnson in the United States and China, supporting brands including: XARELTO®, LEVAQUIN®, TOPAMAX®, ULTRACET®, NUCYNTA®, NUCYNTA® ER and VELCADE®. Nithya holds a BS in Material Science Engineering, with honors, from the University of Florida.
Rhythm is about taking on tough challenges and partnering together across the organization and externally with clinical care teams, patients, and families to advance solutions.